These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 738119)

  • 21. Propafenone in Wolff-Parkinson-White syndrome at risk.
    Santinelli V; Turco P; De Paola M; Smimmo D; Giasi M; Santinelli C; Chiariello M; Condorelli M
    Cardiovasc Drugs Ther; 1990 Jun; 4(3):681-5. PubMed ID: 2076378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of flestolol on ventricular rate during atrial fibrillation in Wolff-Parkinson-White syndrome.
    Swerdlow CD; Peterson J; Liem LB
    Am J Cardiol; 1988 Jul; 62(1):78-82. PubMed ID: 2898208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Onset of atrial fibrillation during antidromic tachycardia: association with sudden cardiac arrest and ventricular fibrillation in a patient with Wolff-Parkinson-White syndrome.
    Cosio FG; Benson DW; Anderson RW; Hession WT; Pritzker MR; Kriett JM; Benditt DG
    Am J Cardiol; 1982 Aug; 50(2):353-9. PubMed ID: 7102563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Usefulness of invasive and non-invasive electrophysiologic studies in the selection of antiarrhythmic drugs for the patients with paroxysmal supraventricular tachyarrhythmia.
    Satake S; Hiejima K; Moroi Y; Hirao K; Kubo I; Suzuki F; Suzuki F
    Jpn Circ J; 1985 Mar; 49(3):345-50. PubMed ID: 3981793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome.
    Kappenberger LJ; Fromer MA; Shenasa M; Gloor HO
    Clin Cardiol; 1985 Jun; 8(6):321-6. PubMed ID: 4006340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Encainide for atrial fibrillation associated with Wolff-Parkinson-White syndrome.
    Rinkenberger RL; Naccarelli GV; Miles WM; Markel ML; Dougherty AH; Prystowsky EN; Heger JJ; Zipes DP
    Am J Cardiol; 1988 Dec; 62(19):26L-30L. PubMed ID: 3144164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of disturbances of cardiac rhythm using intravenous disopyramide].
    Lisin N; Andriange M; Vandenbosch R; Carlier J
    Rev Med Liege; 1974 May; 29(9):256-64. PubMed ID: 4134825
    [No Abstract]   [Full Text] [Related]  

  • 28. Paroxysmal atrial flutter and fibrillation associated with preexcitation syndrome: treatment with ajmaline.
    Sclarovsky S; Kracoff OH; Strasberg B; Lewin RF; Agmon J
    Am J Cardiol; 1981 Nov; 48(5):929-33. PubMed ID: 7304440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Data on disopyridamide therapy of some arrhythmias].
    Perroni GB; Briguglio FS; Oddo A; Trovato G
    Minerva Med; 1977 Jun; 68(32):2271-4. PubMed ID: 69277
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparative analysis of electrophysiologic effect of metoprolol and disopyramide, acting alone or in combination in patients with supraventricular tachycardia and Wolff-Parkinson-White syndrome.
    Bobrov VA; Frolov AI; Mitchenko EI; Galichansky IV; Zinchenko YuV
    Rev Port Cardiol; 1994 Mar; 13(3):221-5. PubMed ID: 8049089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electrophysiological effects of intravenous disopyramide phosphate on the Wolff-Parkinson-White syndrome.
    Tajima T; Dohi Y
    Pacing Clin Electrophysiol; 1982 Sep; 5(5):741-7. PubMed ID: 6182545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of intravenous disopyramide in acute cardiac arrhythmias.
    De Backer M; Stoupel E; Kahn RJ
    Eur J Clin Pharmacol; 1981 Jan; 19(1):11-8. PubMed ID: 6161824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ventricular fibrillation in the Wolff-Parkinson-White syndrome.
    Klein GJ; Bashore TM; Sellers TD; Pritchett EL; Smith WM; Gallagher JJ
    N Engl J Med; 1979 Nov; 301(20):1080-5. PubMed ID: 492252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Oral longterm therapy with disopyramide phosphate in patients with atrial and ventricular arrhythmias (author's transl)].
    Stauch M; Grewe N
    MMW Munch Med Wochenschr; 1977 Dec; 119(48):1563-6. PubMed ID: 74799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atrial and ventricular vulnerability in a patient with the Wolff-Parkinson-White syndrome.
    Peters RW; Gonzalez R; Scheinman MM
    Pacing Clin Electrophysiol; 1981 Jan; 4(1):17-22. PubMed ID: 6171787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Electrophysiologic effects of oral propafenone in Wolff-Parkinson-White syndrome studied by programmed electrical stimulation.
    Sethi KK; Prasad GS; Mohan JC; Arora R; Khalilullah M
    Indian Heart J; 1991; 43(1):5-10. PubMed ID: 1894303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antiarrhythmic effect of disopyramide in ventricular extrasystole and auricular fibrillation].
    Breithardt G; Haerten K; Seipel L
    Z Kardiol; 1976 Aug; 65(8):713-23. PubMed ID: 61664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deleterious effects of intravenous verapamil in Wolff-Parkinson-White patients and atrial fibrillation.
    Strasberg B; Sagie A; Rechavia E; Katz A; Ovsyscher IA; Sclarovsky S; Agmon J
    Cardiovasc Drugs Ther; 1989 Jan; 2(6):801-6. PubMed ID: 2488095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and electrophysiological observations with disopyramide in drug-resistant and recurrent symptomatic arrhythmias.
    Myers JB; Millar RN; Obel IW
    S Afr Med J; 1978 Dec; 54(26):1083-9. PubMed ID: 746466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atrial flutter in Wolff-Parkinson-White syndrome responding to intravenous disopyramide.
    Chia BL; Choo MH; Tan AT; Ee B
    Chest; 1984 Jun; 85(6):820-1. PubMed ID: 6723395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.